Changes in the severity of the menopausal syndrome in the moexipril treatment of essential hypertension

Objective To study the effects of moexipril on the level of blood pressure (BP), the course of the postmenopausal syndrome and the changes occurring in bony tissue in females with mild and mild hypertension in postmenopause Materials and methods Thirty-five females with arterial hypertension were examined All the females were observed to have the menopausal syndrome and reduced bone mineral density To study the effect of moexipril, changes in BP were assessed by its rou tine measurements by means of a sphygmomanometei during control visits before and 1, 3, 6, and 12 months after therapy and by the records available in the BP diaries, bone density was determined by bone ultrasound densitometry before and 12 months after the study Results There was a significant reduction in systolic and diastolic BP by months 1 and 3 of moexipril therapy The manifestations of the menopausal syndrome attenuated by month 6 By the end of the study, the drug showed a significant antiosteopemc activity in the treated females as compared with the untreated ones (p<0,01) Moexipril therapy caused a significant clinical improvement (p<0,05) and a decrease in the degree of reactive anxiety (p<0 05) and depression Conclusion Moexipril is an effective antihypertensive drug whose use normalizes BP in most patients, well tolerated, attenuates the menopausal syndrome, exerts a beneficial effect on bone metabolism The major advantage of the drug is that it can be widely used in postmenopausal women with essential hypertension

postmenopause, essential hypertension, osteoporosis, moexipril

1. Celia M. Oakley Overview Eds HFranz Messerli,F С Aepfelbach Hyper tension in Postmenopausal Women Marsel Dekker Inc New York 1996,1-11

2. Hamson-Bemard L.M., Ray L. Postmenopausal hypertension Curr Hypertens Rep Apr 2000, 2(2) 202-7

3. Cohen E., Wheat M.E., Sutderski D.M., Chamey P. Hypertension in women Eds JHL aragh, BMBrenner Hypertension Pathophysiology, Diagnoisis and Management Second edition (Raven Press Ltd) 1995, P159-69

4. Fisman E.Z., Tenenbaum A., Pines A. Systemic hypertension in postmenopausal women a clinical approach Curr Hypertens Rep Dec 2002,4(6) 464-70

5. Сидоренко Б.А., Сополева Ю.В. Ингибитор ангиотензинпревращающего фермента моэксиприл в лечении артериальной гипертензии у женщин в период после менопаузы Кардиология 1997,6 87-92

6. Кобалава Ж.Д., Морылева О.Н., Котовская Ю.В., Моисеев В.С. Артериальная гипертония после менопаузы лечение ингибитором АПФ мо эксиприлом Клин фармакол и тер 1997,6(4) 69-74

7. Добротворская Т.Е., Мазур Н.А. Артериальная гипертензия у боль ных после наступления менопаузы и ее лечение Московский меди цинский журнал, 1997,4 38-40

8. Hatton К., Stimpel M., Chamders Т. The effect of angiotensin 1 and bradykinin in the presence and absence of moexipnl, and angiotensin 2 on osteoclast formation and activity Submitted for publication

9. Stimpel M < Hypertension after Menopause >, 1997,85-91

10. Рожинская Л.Я. Системный остеопороз M Крон-пресс, 1996